camrelizumab

ESMO 2022 – the new liver cancer entrants line up
EP Vantage
Thu, 09/8/22 - 10:39 am
ESMO
liver cancer
Keytruda
tislelizumab
camrelizumab
Merck
BeiGene
Novartis